Drug Profile
AIR 645
Alternative Names: AIR645; ISIS-369645Latest Information Update: 28 Mar 2012
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Altair Therapeutics
- Class Anti-inflammatories; Antiasthmatics; Antisense oligonucleotides; Oligonucleotides
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Asthma; Rhinitis
Most Recent Events
- 31 Dec 2010 Isis Pharmaceuticals reacquires AIR 645 and related assets from Altair Therapeutics
- 31 Dec 2010 Discontinued - Phase-I for Asthma in Canada (Inhalation)
- 31 Dec 2010 Discontinued - Phase-II for Allergic asthma in Canada (Inhalation)